# US 2013/0280296 A1 · Dna vaccine against multitypes of avian influenza viruses and influenza virus-like particles comprising adjuvant-fused m2 protein

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0280296 A1
- Document ID: US20130280296A1
- Status: Published application
- Kind: A1
- Application number: 13/449,654
- Filed: 2012-04-18
- Published: 2013-10-24
- Earliest claimed: 2012-04-18
- Assignees: National Tsing Hua University
- Inventors: Suh-Chin Wu; Shih-Chang Lin
- Web page: https://patentgrep.com/patent/US20130280296A1

## CPC

- A61K 39/12: Viral antigens
- A61P 31/20: for DNA viruses
- C07K 14/005: from viruses
- A61K 2039/5258: {Virus-like particles}
- A61K 2039/53: {DNA (RNA) vaccination}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/55505: {Inorganic adjuvants}
- A61K 2039/55516: {Proteins; Peptides}
- A61K 2039/6068: {Other bacterial proteins, e.g. OMP}
- C07K 2319/33: fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C07K 2319/60: containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
- C12N 2760/16122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2760/16123: Virus like particles [VLP]
- C12N 2760/16134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

A DNA vaccine comprising hyperglycosylated mutant HA gene, which is derived from avian influenza virus, is provided. A DNA vaccine composition comprising: (a) the DNA vaccine; and (b) a booster is also provided. An influenza virus-like particle comprising adjuvant-fused M2 protein is further provided. A method for eliciting an immune response against a plurality of avian influenza virus subtypes in a subject, comprising delivering the DNA vaccine or the DNA vaccine composition to tissue of the subject is also provided

## Claims

### Claim 1

A DNA vaccine comprising hyperglycosylated mutant HA gene, which is derived from avian influenza virus,
wherein the hyperglycosylated mutant HA gene encodes a protein having one or more mutations at amino acid residue selecting from the group consisting of 83, 86, 94, 127, 138, 161, 182, 252, and the combination thereof.

### Claim 2 (depends on 1)

The DNA vaccine of claim 1, wherein the hyperglycosylated mutant HA gene encodes a protein comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 4, 6, 8, 10, 12, 14, 16, 18, and 20.

### Claim 3 (depends on 1)

The DNA vaccine of claim 1, wherein the hyperglycosylated mutant HA gene encodes a protein comprising an amino acid sequence of SEQ ID NOs: 4, 6, or 10.

### Claim 4 (depends on 1)

The DNA vaccine of claim 1, which elicits an immune response against a plurality of avian influenza virus subtypes in a subject.

### Claim 5 (depends on 1)

A DNA vaccine composition comprising:
(a) a DNA vaccine of claim 1; and
(b) a booster.

### Claim 6 (depends on 5)

The DNA vaccine composition of claim 5, wherein the booster is an influenza virus-like particle (VLP).

### Claim 7 (depends on 6)

The DNA vaccine composition of claim 6, wherein the influenza virus-like particle is derived from cell infected by recombinant baculoviruses comprise one or more plasmids containing HA gene, M1 gene, NA gene and FliC-M2 gene, which encodes FliC-M2 fusion protein.

### Claim 8 (depends on 5)

The DNA vaccine composition of claim 5, which further comprises an adjuvant.

### Claim 9 (depends on 8)

The DNA vaccine composition of claim 8, wherein the adjuvant is an aluminum-containing adjuvant.

### Claim 10 (depends on 5)

The DNA vaccine composition of claim 5, wherein the DNA vaccine and the booster have a mass ratio of 5 to 3.

### Claim 11 (depends on 5)

The DNA vaccine composition of claim 5, which elicits an immune response against a plurality of avian influenza virus subtypes in a subject.

### Claim 12

An influenza virus-like particle comprising adjuvant-fused M2 protein.

### Claim 13 (depends on 12)

The influenza virus-like particle of claim 12, which further comprises HA protein, NA protein and M1 protein.

### Claim 14 (depends on 12)

The influenza virus-like particle of claim 12, wherein the adjuvant is flagellin or profilin.
